Polarean Imaging plc.’s technology is for research use only

Polarean Technology Used in Severe Asthma Study

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, notes the publication of a study using Polarean's hyperpolarised gas MRI technology in a study of patients with severe asthma in the April edition of the American Journal of Respiratory and Critical Care Medicine (AJRCCM).

The study, entitled "Sputum Eosinophilia and Magnetic Resonance Imaging Ventilation Heterogeneity in Severe Asthma" is authored by Svenningsen, Eddy, Lim, Cox, Nair and Parraga and can be obtained from the AJRCCM website.

The study looked at patients with severe asthma and investigated the contributions of both inflammatory and non-inflammatory components of airway disease. A key finding was that MRI scans using hyperpolarized gas were able to identify, for the first time, the airway inflammatory (eosinophilia) and non-inflammatory contributions (smooth muscle dysfunction) to ventilation heterogeneity in patients with severe asthma.

learn more about it

Polarean will be exhibiting at the 26th ISMRM Annual Meeting and Exhibition in Paris, June 16-21, 2018. Please visit us at booth #341 to learn more about Polarean’s latest technical advances in Hyperpolarized Gas MRI technology, including high-throughput polarized xenon production, advances towards regulatory approval and various ways to start your xenon imaging research program or upgrade existing equipment.